CBG-258

N/A

Report date: 2025/03/26 16:03:18

Base Information

Drug NameCBG-258
Drug Alias NameCBG258CBG-258
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCarbiogene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuadong Medicine Co LtdCarbiogene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A